GAITHERSBURG, Md., Aug. 26, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a leader in AI-driven drug discovery, announced today that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference being held in New York City.
Interested parties may access live and archived webcasts of these events on the company’s investor relations website at: investors.bullfrogai.com. The Company’s presentation by Vin Singh, Chief Executive Officer, will be available on demand commencing on September 9, 2024, at 7:00am ET.
About BullFrog AI
BullFrog AI leverages Artificial Intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP™ platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials. For more information, visit BullFrog AI at www.bullfrogai.com.
Contact:
Investors
Dave Gentry
RedChip Companies, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-407-644-4256
| Last Trade: | US$1.66 |
| Daily Volume: | 228,570 |
| Market Cap: | US$14.460M |
February 27, 2025 October 22, 2024 October 21, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
